CXCR4 and type 2 diabetes mellitus: When compared to patients with T2DM treated with glimepiride, the group that received sitagliptin for 12 weeks showed an obvious increase in the circulating EPC count, and the effect was likely mediated by the SDF-1α/CXCR4 axis (31).